


Brigimadlin

Chemical Properties

CAS No. :	2095116-40-6
Formula:	C ₃₁ H ₂₅ Cl ₂ FN ₄ O ₃
Molecular Weight:	591.46
Storage:	Keep away from direct sunlight, Store at low temperature Store at -20°C

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Brigimadlin (BI 907828) is an orally active and highly potent E3 ubiquitin-protein ligase MDM2-p53 antagonist with antitumor activity. Brigimadlin can be used to study metastatic BTC, PDAC, lung adenocarcinoma, or bladder cancer.
Targets(IC50)	Mdm2, E1/E2/E3 Enzyme, p53, MDM-2/p53
In vitro	Brigimadlin (at concentrations ranging from 0-10 nM; over 48 hours) inhibits the proliferation of BT48, BT50, BT67, BT69, BT89, and BT94, with respective IC50 values of 58.5, 21.1, 37.9, 89.8, 16.7, and 46.8 pM[1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6907 mL	8.4537 mL	16.9073 mL
5 mM	0.3381 mL	1.6907 mL	3.3815 mL
10 mM	0.1691 mL	0.8454 mL	1.6907 mL
50 mM	0.0338 mL	0.1691 mL	0.3381 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Hao X, et al. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. *Neuro Oncol.* 2023 May 4;25(5):913-926.
- Yoo C, et al. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. *Future Oncol.* 2024 Jan 12.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481